吉西他滨联合奈达铂治疗晚期非小细胞肺癌疗效观察

目的观察吉西他滨联合奈达铂治疗晚期非小细胞肺癌的疗效及毒副反应。方法23例入选病例均为Ⅲ/Ⅳ期非小细胞肺癌。给予吉西他滨1000mg/m^2,静脉滴注d1,d8; 奈达铂80mg/m^2,静脉滴注d1。28d为1周期,4个疗程后评价疗效。结果23例患者均可评价疗效及不良反应,CR2例,PR12例,总有效率为60.9%,中位生存期11.3个月,一年生存率51.7%。主要毒副反应为骨髓抑制和消化道不良反应,无化疗相关死亡。结论吉西他滨联合奈达铂治疗晚期非小细胞肺癌疗效好,不良反应可耐受,值得临床应用。

Curative Effectiveness of Gemcitabine Combined with Nedaplatin for Advanced Non-small Cell Lung Cancer

Objective To evaluate clinical efficacy and toxicity of Gemcitabine combined with Nedaplatin for advanced non-small cell lung cancer.Methods A total of 23 patients with advanced non-small cell lung cancer（grade Ⅲ to Ⅳ） received Gemcitabine 1 000 mg/m^2（iv gtt Day1,8） and Nedaplatin 80 mg/m^2（iv gtt Day1）.28 days were as a cycle.The clinical efficacy was evaluated after 4 treatment courses.Results 23 patients were involved in clinical efficacy and toxicity evaluation.CR：2 cases,PR：12 cases,and the response rate was 60.9%.The median survive time was 11.3 months;1-year survival rate was 51.7%.The toxicity was mainly the bone marrow depression and peptic toxicity that were tolerable.There was no death cases in the chemotherapy.Conclusion Gemcitabine combined with Nedaplatin has a relative high response rate and low toxicity in the treatment of advanced non-small cell lung cancer.